Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse  Samuel B. Ho, Norbert Bräu, Ramsey Cheung, Lin Liu, Courtney Sanchez, Marisa Sklar, Tyler E. Phelps, Sonja G. Marcus, Michelene M. Wasil, Amelia Tisi, Lia Huynh, Shannon K. Robinson, Allen L. Gifford, Steven M. Asch, Erik J. Groessl  Clinical Gastroenterology and Hepatology  Volume 13, Issue 11, Pages 2005-2014.e3 (November 2015) DOI: 10.1016/j.cgh.2015.02.022 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Patient enrollment and randomization. All HCV clinic patients were screened as part of standard clinical care. PCL, primary care PTSD screen checklist. Clinical Gastroenterology and Hepatology 2015 13, 2005-2014.e3DOI: (10.1016/j.cgh.2015.02.022) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 (A) Antiviral treatment initiation over time in the IC vs the UC group. Antiviral treatment periods are indicated for PEG + RBV and DAA + PEG + RBV. The y-axis shows the cumulative number of patients initiating treatment. Final treatment initiation rates were as follows: IC, 58 of 182 (31.9%); UC, 34 of 181 (18.8%) (P = .005). (B) Cumulative probability of treatment initiation by treatment group over time (months). Patients were censored at the end of the study follow-up period. ne, number of events (treatment initiation); PEG, pegylated interferon alfa; RBV, ribavirin. Clinical Gastroenterology and Hepatology 2015 13, 2005-2014.e3DOI: (10.1016/j.cgh.2015.02.022) Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 Adherence to planned therapy and virologic outcomes in IC vs UC. (A) Amount of adherence to planned duration of therapy. The percentage of treated patients who adhered to the indicated percentage of planned therapy. (B) On-treatment virologic response and SVR at 12 or 24 weeks for patients initiating therapy. LLOQ, lower limit of quantification. (C) Overall percentage of patients with SVR in each group. Clinical Gastroenterology and Hepatology 2015 13, 2005-2014.e3DOI: (10.1016/j.cgh.2015.02.022) Copyright © 2015 AGA Institute Terms and Conditions